Top Story

Mismatch repair deficiency predicts response to pembrolizumab in several cancer types

May 29, 2015

Read the Perspective from Lynn M. Schuchter, MD, FASCO

CHICAGO — Mismatch repair deficiency may be the first genomic marker to predict how patients with cancer will respond to immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab, according to phase 2 study results presented at the ASCO Annual Meeting.

An analysis that included patients with several cancer types showed those with mismatch repair (MMR)-deficient tumors demonstrated a dramatically higher response rate and significantly longer PFS after treatment with pembrolizumab (Keytruda, Merck) than those who did not have the abnormality, characterized as MMR proficient.

Meeting News Coverage

Post-hospital prophylaxis could reduce risk for venous thromboembolism, death after lung resection

May 29, 2015
The incidence of post-operative venous thromboembolism following oncologic lung resections and after discharge is significant, despite guidelines directing prophylaxis…
In the Journals

CDC: Cancer screening rates remain below Healthy People 2020 targets

May 29, 2015
 The number of adults in the U.S. who underwent the recommended screening tests for breast, colorectal and cervical cancers in 2013 fell below the targets set by…
In the Journals

Mohs micrographic surgery for melanoma increased from 2003 to 2008

May 29, 2015
Use of Mohs micrographic surgery to treat melanomas increased by 60% between 2003 and 2008, according to data from the National Cancer Institute. Researchers used data…
More News Headlines »
Health Care Legislative and Regulatory Update Perspective
Obama signs Medicare Access and CHIP Reauthorization Act of 2015 into law

Obama signs Medicare Access and CHIP Reauthorization Act of 2015 into law

Orthopedics Today, May 2015
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory…
More »
Meeting News Coverage Video
VIDEO: Updates in prostate cancer treatment options

VIDEO: Updates in prostate cancer treatment options

May 5, 2015
Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, discusses various forms of prostate cancer…
More »
morganatic-roan